PEPCID
LOE ApproachingNDAORALTABLET
Approved
Oct 1986
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PEPCID (famotidine) is an oral histamine H2-receptor antagonist approved in 1986 for gastrointestinal acid-related disorders. It reduces stomach acid production and is used to treat and prevent peptic ulcers, gastroesophageal reflux disease (GERD), and other acid-related conditions. The drug works by blocking histamine-2 receptors on gastric parietal cells, decreasing gastric acid secretion.
$0.836MPart D
LOE ApproachingLow Part D utilization ($836K across 547 claims in 2023) suggests limited branded presence, likely due to OTC availability and generic competition.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
PEPCID shows zero linked job openings, reflecting its status as a mature, low-priority branded product within Bausch + Lomb's portfolio. Career opportunities on this product are minimal and likely limited to legacy support roles rather than growth-oriented positions.
Company
Worked on PEPCID at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.